Previously, CMS determined that coverage for patients receiving treatment was dependent on their being enrolled in a CMS-approved clinical trial under coverage with evidence development (CED).

FDG-PET scans in these patients allow clinicians to determine whether the tumors are still viable or not, thus playing a significant role in making treatment decisions.

Munir Ghesani, MD, president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and system chief of nuclear medicine at Mount Sinai Health, explains PSMA-PET has seen rapid adoption because it can significantly improve prostate cancer detection and treatment. 
 

A new study in JACC: Cardiovascular Imaging focuses on a potential new side effect of COVID-19, highlighting the continued importance of monitoring these patients going forward. 

In the study, patients who had recovered from an COVID infection were injected with a small amount of the 89Zr-labeled radiotracer before undergoing a uExplorer PET/CT scan.

Better risk stratification can improve clinical decision making and better outcomes, experts involved in the study explained in EJR.

A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality.